Sulbactam-Durlobactam for Drug-Resistant Bacterial Infections
Part of Infections, Lungs & breathing clinical trials.
This study tracks hospitalized patients receiving a specific antibiotic combination (sulbactam-durlobactam) to treat a serious, hard-to-treat bacterial infection called CRAB. Researchers want to understand how well this treatment works in real-world hospital settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You are currently hospitalized and receiving treatment for a confirmed CRAB infection (a drug-resistant bacterial infection), or you received a transplant and have CRAB from the donor
- Your doctors can clearly identify when your antibiotic treatment started
- Your medical records have complete information about your treatment and outcomes
- You are not pregnant or breastfeeding
- You do not have CRAB colonization (bacteria present) without signs of active infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This study tests whether giving certain antibiotics intermittently versus continuously, along with a second antibiotic, works better for hospital-acquired sepsis. It may help doctors choose the most effective way to control serious infections.
This study checks how safe sulbactam-durlobactam (a combination antibiotic) is in adults with a serious infection caused by ABC bacteria, especially looking for allergic reactions. If you are already getting this antibiotic as part of your care, you may be able to join.
This trial tests a new combination of antibiotics (sulbactam-durlobactam) for children with a serious infection caused by Acinetobacter bacteria. The goal is to see if this treatment is safe and works well for kids.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This trial tests two different antibiotic combinations (ampicillin/sulbactam and cefoperazone/sulbactam) to see which works better against a type of bacteria (Acinetobacter baumannii) that is resistant to many other drugs. It is for critically ill patients with signs of sepsis.
Hear when a new Bloodstream Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.